Abstract
Anoxia halts oxidative phosphorylation (OXPHOS) causing an accumulation of reduced compounds in the mitochondrial matrix which impedes dehydrogenases. By simultaneously measuring oxygen concentration, NADH autofluorescence, mitochondrial membrane potential and ubiquinone reduction extent in isolated mitochondria in real-time, we demonstrate that Complex I utilized endogenous quinones to oxidize NADH under acute anoxia. 13C metabolic tracing or untargeted analysis of metabolites extracted during anoxia in the presence or absence of site-specific inhibitors of the electron transfer system showed that NAD+ regenerated by Complex I is reduced by the 2-oxoglutarate dehydrogenase Complex yielding succinyl-CoA supporting mitochondrial substrate-level phosphorylation (mtSLP), releasing succinate. Complex II operated amphidirectionally during the anoxic event, providing quinones to Complex I and reducing fumarate to succinate. Our results highlight the importance of quinone provision to Complex I oxidizing NADH maintaining glutamate catabolism and mtSLP in the absence of OXPHOS.
Subject terms: Biochemistry, Metabolomics
Introduction
All mammalian mitochondria harbor Complex I (CI, NADH:ubiquinone oxidoreductase, EC 1.6.5.3). CI catalyzes the oxidation of matrix NADH by ubiquinone (UQ) to produce NAD+ and ubiquinol (UQH2), which is coupled to the translocation of four H+ across the mitochondrial inner membrane and the transfer of electrons downstream to FeS clusters1. Mindful of the limitations in quantifying NADH oxidation by CI2 and the enhancement of NADH autofluorescence by mere binding to CI3, it is difficult to decipher the extent of the contribution of CI in altering the mitochondrial NADH/NAD+ ratio. Nevertheless, it is a textbook definition that cessation of the electron transfer system (ETS) due to lack of oxygen, pharmacological inhibition or genetic ablation of respiratory components leads to an accumulation of reduced compounds in the mitochondrial matrix, exactly because CI is not able to oxidize NADH. In turn, this increase in matrix NADH/NAD+ ratio is expected to impair the function of matrix dehydrogenases, preventing mitochondria from catabolizing substrates in the citric acid cycle4. Having said that, the catabolism of glutamine through oxidative decarboxylation of 2-oxoglutarate (oxoglutarate, Og, α-ketoglutarate) during hypoxia has been unequivocally demonstrated5. The question arises, what provides NAD+ to 2-oxoglutarate dehydrogenase complex (OgDHC) in hypoxia? Using a battery of untargeted and targeted 13C metabolic tracer analyses, biochemical, electrochemical and fluorescence assays, we report that in isolated murine mitochondria experiencing acute true anoxia or in the presence of cyanide, the residual activity of CI is sufficient to provide NAD+ to OgDHC and maintain the oxidative decarboxylation branch of 2-oxoglutarate supporting mitochondrial substrate-level phosphorylation (mtSLP). We further show that during the anoxic event Complex II (CII, succinate:ubiquinone oxidoreductase, EC 1.3.99.1) operates amphidirectionally, providing quinones to Complex I and reducing fumarate to succinate.
Materials and methods
All methods were carried out in accordance with relevant guidelines and regulations of the Semmelweis University.
All methods reported are in accordance with the ARRIVE guidelines (https://arriveguidelines.org).
Experimental model and subject details
Animals
Mice were of C57Bl/6N or 6J (the latter only for the right panels of main figure 6 and supplementary figure panels 8K and 8L) or 129/Sv (for main figure 6, left panels) background. The animals used in our study were of either sex and between 2 and 6 months of age. Mice were housed in a room maintained at 20–22 °C on a 12-h light–dark cycle with food and water available ad libitum, unless otherwise indicated. For preparation of mitochondria from their organs, mice were killed by cervical dislocation without euthanasia. The study was approved by the Animal Care and Use Committee of the Semmelweis University (Egyetemi Állatkísérleti Bizottság, protocol code F16-00177 [A5753-01]; date of approval: May 15, 2017). All procedures regarding animals complied with the ARRIVE guidelines.
Mitochondrial isolation
Liver and heart mitochondria from all animals were isolated as described in6 with minor modifications. Mice were killed by cervical dislocation without euthanasia. The organs were rapidly removed and immediately placed in ice-cold isolation buffer, the composition of which was, for liver: 225 mM mannitol, 75 mM sucrose, 5 mM HEPES (free acid), 1 mM EGTA and 1 mg/ml bovine serum albumin (fatty acid-free), with the pH adjusted to 7.4 with Trizma®, and for heart: 100 mM KCl, 50 mM Trizma, 5 mM MgCl2, 2 mM EGTA and 2.5 mg/ml bovine serum albumin (fatty acid-free), with the pH adjusted to 7.4 with HCl, to which 1 mM ATP was just freshly added. Next, the organs were chopped, washed, homogenized and the homogenate was centrifuged at 1,250 g for 10 min. The upper fatty layer of the centrifuged homogenate was aspirated and the pellet was discarded. The remaining supernatant was centrifuged at 10,000 g for 10 min. After this step the supernatant was discarded and the pellet was resuspended in isolation buffer, and centrifuged again at 10,000 g for 10 min. At the end the pellet was resuspended in 0.2 ml of a buffer with the same composition as the liver isolation buffer but with 0.1 mM EGTA. Non-synaptic brain mitochondria were isolated on a Percoll gradient as described previously7 , with minor modifications detailed in8. Protein concentration was determined using the bicinchoninic acid assay, and calibrated using bovine serum standards9 using a Tecan Infinite® 200 PRO series plate reader (Tecan Deutschland GmbH, Crailsheim, Germany).
Determination of membrane potential (ΔΨmt)
ΔΨmt of isolated mitochondria (0.5–1 mg mitochondria in 2 mL buffer medium, the composition of which was 8 mM KCl, 110 mM K-gluconate, 10 mM NaCl, 10 mM Hepes, 10 mM KH2PO4, 0.01 mM EGTA, 10 mM mannitol, 1 mM MgCl2, 0.5 mg/ml bovine serum albumin (fatty acid-free), pH 7.25, containing substrates as indicated in the figure legends) was estimated fluorimetrically with 5 µM rhodamine 12310. Fluorescence was recorded using the NextGen-O2k prototype equipped with the O2k-Fluo Smart Module, with optical sensors including a LED (465 nm; < 505 nm short-pass excitation filter), a photodiode and specific optical filters (> 560 nm long-pass emission filter)11. Experiments were performed at 37 °C.
Mitochondrial respiration
Oxygen consumption was monitored polarographically using an Oxygraph-2k. 0.5–1 mg of mitochondria were suspended in 2 ml incubation medium, the composition of which was identical to that for ΔΨmt determination. Experiments were performed at 37 °C. Oxygen concentration (µM) and oxygen flux (pmol·s −1·mg −1; negative time derivative of oxygen concentration, divided by mitochondrial mass per volume and corrected for instrumental background oxygen flux arising from oxygen consumption of the oxygen sensor and back-diffusion into the chamber) were recorded using DatLab software (Oroboros Instruments).
Determination of NADH autofluorescence
NADH autofluorescence was measured using the NADH-Module of the NextGen-O2k (Oroboros Instruments) or a Hitachi F-7000 fluorescence spectrophotometer, as indicated in the text. The NextGen-O2k allows simultaneous measurement of oxygen consumption and NADH autofluorescence, incorporating an ultraviolet (UV) LED with an excitation wavelength of 365 nm and an integrated spectrometer which records a wavelength range between 450 and 590 nm. The light intensity of the LED was set to 10 mA. 0.5–1 mg of mitochondria were suspended in 2 mL incubation medium, the composition of which was identical to that for ΔΨmt determination, as described in12. Experiments were performed at 37 °C.
NADH alkaline extraction and quantification
NADH was extracted and quantified in isolated mouse liver mitochondria as described in13, with minor modifications. Briefly, 2 mg mitochondria in 2 ml were incubated as described above under mitochondrial respiration. Reactions were stopped by the addition of 50 µl 52.9 wt% KOH in water, and 50 µl ethanol was added to 100 µl samples. After 30 min the solution was neutralized with a 0.4 M Tris, 0.6 M KH2PO4 mixture and left to flocculate for 10 min. The suspension was centrifuged and 2 µl 1 M pyruvate was added to 200 µl supernatant, oxidation of NADH was measured by the decrease in fluorescence (340 nm Ex., 435 nm Em.) upon the addition of 1 µl 96.8 U/ml bovine H-type LDH in a white 96 well plate. Fluorescence was calibrated by standard addition of 1 µl 0.1 mM NADH. Each measurement was done with technical triplicates.
Mitochondrial Q redox state
Coenzyme UQ redox state of isolated mitochondria suspended in a buffer composition identical to that for ΔΨmt determination was followed amperometically using a three electrode system described in14,15 but with coenzyme Q2 (CoQ2, 1 µM) as mediator, using the Q-Module of the NextGen-O2k16,17. The reference electrode was Ag/AgCl/(3M KCl). The auxiliary electrode was made of platinum and the working electrode was fabricated from glassy carbon. The three electrode system has been validated in16,17. Oxidation peak potential of CoQ2 measured by cyclic voltammetry was set to the glassy carbon to measure the oxidation of reduced CoQ2. UQ redox state was recorded simultaneously with O2 flux and rhodamine 123 fluorescence. Arbitrarily, we assigned the effect of ADP and anoxia as the 100% and 0% internal reference points of UQ oxidized state scale, respectively. All drugs used in this study were verified not to exert any artefactual alterations on the electrodes of the Q module using cyclic voltammetry, shown in supplementary Fig. 17.
Mitochondrial swelling
Swelling of isolated mitochondria was assessed by measuring light scatter at 520 nm (37 °C) in a Hitachi F-7000 fluorescence spectrophotometer. 0.5 mg of mouse liver mitochondria were suspended in 2 ml incubation medium, the composition of which was identical to that for ΔΨmt determination. Experiments were performed at 37 °C. Anoxic conditions were achieved by manufacturing a custom-made plug for polymethacrylate cuvettes by 3D-printing. The plug 3D design and instructions for use are published in https://www.thingiverse.com/thing:3156148. At the end of each experiment, the non-selective pore-forming peptide alamethicin (40 μg) was added as a calibration standard to cause maximal swelling.
Prothrombin time measurement
Blood samples were taken from the saphenous vein in 110 mM Na3-citrate (citrate/blood volume ratio 1:10), as described in18. After centrifugation at 2500g for 15 min the plasma supernatant was collected and used for the measurement within 4 h. Prothrombin time was measured with Technoplastin-HIS reagent (Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, Vienna, Austria) in a coagulometer KC-1A (Amelung, Lemgo, Germany) as the time to form clots from 100 µl plasma diluted twofold in 10 mM HEPES 150 mM NaCl pH 7.4 buffer by 200 µl Technoplastin-HIS reagent.
Untargeted metabolite analysis
Mitochondrial suspensions were ’spiked’ with 1 mM L-norleucine, a non-metabolizable substrate that yields a highly recognizable signature during the metabolite analysis and was used for normalizing volumes and keeping pipetting errors at check. At specified times during the experiments (indicated in the text) three 0.6 mL aliquots from the 2 mL mitochondrial suspensions were spun at 14,000 rpm for 5 min at 4 °C. Supernatants (0.5 mL) were separated from the pellets. Any remaining visible aqueous phase was removed from the pellets and discarded. Both pellets and supernatants were transferred to new tubes and to each tube 0.5 mL of ice-cold 80% methanol was added. The tubes were snap frozen in liquid nitrogen during processing to ensure samples were kept cold and transferred to − 80 °C until further processing. Approximately two days later, samples were sonicated for 10 min at room temperature and then centrifuged at 14,000 rpm for 10 min at 4 °C. All of the supernatants were removed, transferred to Eppendorf tubes and evaporated to dryness overnight using a centrifugal evaporator. Once dry, the dried lysates were stored at − 80 °C until further analysis. Dried lysates were reconstituted in 2:1:1 acetonitrile:MeOH:H2O, to yield a concentration of 200 mg/mL and spun at 14,000 rpm for 10 min at 4 °C to remove excess debris before analysis. Chromatography was performed using an Agilent 1290 Infinity UPLC. Ten microliters of each sample were injected onto a ZIC-pHILIC column (EMD Millipore, Billerica, MA) with dimensions of 150 × 4.6 mm, 5 μm. Metabolites were separated using an acetonitrile/H2O with 20 mM ammonium carbonate (pH 9.2) gradient over a 29-min period. A 10-min re-equilibration time was carried out in between injections. Detection was performed using an Agilent 6550 quadrupole-time-of-flight (QToF) mass spectrometer, operated in both negative and positive modes. Full scan MS data was collected from m/z 70–1000 and metabolites were identified in an untargeted manner by looking within 10 ppm of the expected m/z values. Real-time mass calibration was performed throughout the duration of sample analysis. Data was processed using a publically available software package, MAVEN19. Area under the chromatographic peak for each metabolite was calculated and exported to assess differences in metabolite abundances.
Targeted 13C metabolic tracer analysis
[U-13C]glutamate (5 mM) or [U-13C]malate (2.5 mM) was added to the mitochondrial suspensions, as indicated in the text. Metabolites extraction was performed similar to the untargeted metabolite analysis, with the exception that in the supernatants, 1 mM methionine was added for normalizing volumes, as it also yields a highly recognizable signature during the analysis. Dried lysates were derivatized using a two-step protocol. Samples were first treated with 2% methoxamine in pyridine (40 μL, 1 h at 60 °C), followed by addition of N-(tert-butyldimethylsilyl)-N-methyl-trifluoroacetamide, with 1% tert-butyldimethylchlorosilan (50 μL, 1 h at 60 °C). Samples were transferred to glass vials for GC–MS analysis using an Agilent 8890 GC and 5977B MSD system. 1 μL of sample was injected in splitless mode with helium carrier gas at a rate of 1.0 mL.min−1. Initial GC oven temperature was held at 100 °C for 1 min before ramping to 160 °C at a rate of 10 °C.min−1, followed by a ramp to 200 °C at a rate of 5 °C.min−1 and a final ramp to 320 °C at a rate of 10 °C.min−1 with a 5 min hold. Compound detection was carried out in scan mode. Total ion counts of each metabolite were normalized to the internal standard norleucine (supernatants) or methionine (pellets).
Quinones extraction
2 mg mitochondria were suspended in a solution of 5 mM ferricyanide, 100 mM Tris, pH 8.0. Proteins were precipitated by addition of methanol triple the aqueous volume, followed by extraction three times with light petroleum (bp. 40–60 °C). After evaporation of the solvent from the extract, the residues were dissolved in ethanol and the absorption measured at 275 nm before and after stepwise additions of a 5 g/L borohydride solution in a 1 cm path length cuvette. Quinone concentration was calculated with the oxidized-reduced difference absorbance Δε275 nm = 12.5 mM−1 cm−1, reported in20.
Blue-native gel electrophoresis, western blot and immunodetection
The analysis of the super-assembly state of Complex I was performed as described previously21. Briefly, frozen mitochondrial pellets were resuspended at a protein concentration of 10 mg/ml in solubilization buffer (1.5 M aminocaproic acid, 50 mM Bis–Tris/HCl pH 7.0) and the mitochondrial membranes were solubilized using a digitonin to protein ratio of 4:1. The cleared lysate was mixed with sample buffer [0.75 M aminocaproic acid, 50 mM Bis–Tris–HCl pH 7.0, 0.5 mM EDTA, 5% SERVA Blue G (Coomassie Brilliant Blue G-250)] and approximately 15 µg of mitochondrial protein were loaded in each lane of precast native 3%-13% gradient gels (Invitrogen) and run according to the manufacturer’s instructions. Once the front reached the end of the gel, the electrophoresis was stopped and the native complexes were blotted onto PVDF membranes and immunodetected. Complex I was specifically detected using an antibody against NDUFS1 (RRID: AB_2687932) and Complex II was detected with an anti-SDHB antibody (RRID: AB_301432). For signal detection, Goat anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ Plus 800 (RRID: AB_2633284) and Goat anti-Mouse IgG (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 680 (RRID: AB_2535723) were used and the images were captured using an Odyssey CLx instrument (Li-Cor Biosciences).
Reagents
Mitochondrial substrates were dissolved in bi-distilled water and titrated to pH 7.0 with KOH. ADP was purchased as a K+ salt of the highest purity available (Merck) and titrated to pH 6.9. Concentrations of glutamate (G), malate (M), succinate (S), fumarate (Fum) and oxoglutarate (Og) were always 5 mM when present, unless otherwise indicated. ADP concentrations were 2 mM. Rotenone (Rot, 1 µM), myxothiazol (Myx, 0.1 µM), stigmatellin (Stigm, 0.5 µM) carboxyatractyloside (CAT, 1 µM), SF6847 (SF, 0.25 µM), piericidin A (Pierc, 1 µM), pyridaben (Prdb, 1 µM), atpenin A5 (Atpn, 1 µM), malonate (Mna, 5 mM), cyanide (NaCN or KCN, CN, 1 mM), arsenite (Arsn, 1 mM or 2 mM). Both myxothiazol and stigmatellin block CIII; they have been used in our experiments according to availability.
Quantification and statistical analysis
Statistics
Data are presented as averages ± SEM. Significant differences between two groups were evaluated by Student's t-test or Mann–Whitney U Test if normality failed. Significant differences between three or more groups were evaluated by one-way ANOVA or ANOVA on Ranks if normality failed; statistical significance was accepted when p < 0.05 (shown as *). The number of experiments is indicated in the figure legends. Regarding figure panels 4K, 4L, 4M and supplementary figure panels 14E and 14F: Combined standard uncertainty was calculated using Gauss’ law of error propagation with linear approximation using the NIST uncertainty machine v1.5. Subsequently, covariance between succinate isotopologue amount fractions and between 2-oxoglutarate isotopologue amount fractions were taken into account, although the correction was negligible. No other consistent correlation was found among the uncertainties.
Results
Complex I remains partially active during acute anoxia
Mindful that CI oxidizes one molecule of NADH to NAD+ by reducing UQ to UQH2 in an equimolar manner while pumping four protons out of the matrix as shown in Fig. 1A, Jin and Bethke derived a model for CI activity using non-equilibrium thermodynamics22. We used their rate equation to generate a 3D plot of CI activity (expressed in nmol e−min−1 mg−1) and input very wide ranges of UQH2/UQ and NAD+/NADH ratio reported in the literature23–27. As shown in Fig. 1B, when UQH2/UQ is > 10 and NAD+/NADH < 1 mimicking anoxic conditions, CI activity is predicted to retain < 20% of its theoretical maximum. We therefore set to investigate (i) if CI activity can indeed be experimentally demonstrated under anoxic conditions and (ii) whether the fluxes of the reaction products, i.e. NAD+ and UQH2 are sufficiently high for maintaining downstream processes and—if yes—to which extent. As a first step, we set up an assay to simultaneously monitor the ETS-reactive Q redox state, NADH autofluorescence, O2 concentration and membrane potential (ΔΨmt) during anoxia, in a (sub)second scale. We mostly used isolated mouse liver mitochondria because of the high yield, purity and level of intactness achieved in this preparation28, however, several experiments were performed and interpretations verified by using brain and heart mitochondria (see below and supplementary Figs. 4 and 5). [O2] was detected polarographically, ΔΨmt fluorimetrically (inferred from rhodamine 123 preloading), NADH by its autofluorescence, and the ETS-reactive Q redox state electrochemically using coenzyme Q2 as a mediator between the mitochondrial UQ pool and the electrodes 14,17. All species that have a connection to endogenous ubiquinone through the so-called “coenzyme Q junction” 29–31 can contribute to the electrochemical reaction, including the endogenous ubiquinone itself present in the mitochondrial inner membrane, by reducing Q2. The electrochemical properties of the two (endogenous and Q2) are virtually identical owing to the difference being only in the distant hydrophobic chain and therefore can be considered to be close to an equilibrium. However, it is still possible to observe different properties due to the differential solubility and enzyme affinities. Other artificial reactions may also be considered, such as oxidation by dissolved oxygen, but over the experiments conducted, qualitatively no significant deviation was observed compared to just treating it as a representation of the endogenous ETS-reactive ubiquinone (Q) pool, which it is in equilibrium with. This is further supported by the lack of other electrochemically active compounds during cyclic voltammetry shown in supplementary Fig. 17. Rhodamine 123 fluorescence indicative of ΔΨmt (arbitrary units, a.u.) was recorded separately from NADH autofluorescence due to spectral overlap. As shown in Fig. 1C [O2], UQ % and rhodamine 123 fluorescence (indicative of ΔΨmt) were measured simultaneously in the same sample (panels are aligned in the x-axis); in Fig. 1E NADH % is depicted, measured in another sample simultaneously to [O2] and ΔΨmt. Mitochondria were added where indicated, followed by ADP inducing OXPHOS respiration. The CI-specific inhibitor rotenone (Rot) or vehicle (veh) was added before (supplementary Figs. 1A, D) or after (Fig. 1C, E, and supplementary Figs. 1B, E) the chamber was depleted from O2 (in the figure panels marked as “anoxia”). Upon induction of anoxia the oxygen sensor detects no further changes in O2 concentration (Fig. 1C and supplementary Fig. 1B, top panels); for detailed description of the sensor response during the transition from normoxic to anoxic conditions, see 32. Anoxia was associated with near simultaneous, precipitous reduction of UQ (Fig. 1C, supplementary Fig. 1B, middle panels) and increases in rhodamine 123 fluorescence (indicative of depolarization, Fig. 1C and supplementary Fig. 1B bottom panels) and abrupt increases in NADH autofluorescence (Fig. 1E and supplementary Fig. 1E). As expected, ADP and anoxia conferred an increase- vs a decrease in Q oxidation levels (Figs. 1C and supplementary Fig. 1B, middle panels), respectively, and accordingly, a decrease- vs an increase in NADH levels (Figs. 1E and supplementary Fig. 1E). However, it is also obvious that rotenone inhibited UQ reduction to UQH2 whether O2 was present (supplementary Fig. 1A, middle panel) or not (Fig. 1C, middle panel). The spikes (pseudocolored in green in middle panels 1C, supplementary Fig. 1B) are artefacts produced by the addition of chemicals; from such experiments we pooled the values in the Q signals conferred by the additions (as indicated by the bidirectional arrow in 1C, middle panel) and show them in bar graphs in figure panel 1D. Furthermore, addition of rotenone to anoxic mitochondria yielded a further increase in NADH fluorescence (Fig. 1E). Pooled values in NADH signals conferred by the additions (indicated by the bidirectional arrow) are shown in bar graphs in figure panel 1F (NADH levels after the addition of ADP and commencement of anoxia were arbitrarily assigned as the 0% and 100% internal reference points of the scale, respectively). The rotenone-induced changes in NADH could also be observed when mitochondria were treated with NaCN (1 mM) to confer ‘chemical anoxia’, instead of true anoxia. Representative traces are shown in Fig. 1H; in trace a, vehicle (veh) is added where indicated, and in trace (b), rotenone. Quantification of the rotenone-induced change in NADH fluorescence in CN-treated mitochondria is shown in Fig. 1I. Accordingly, changes in rhodamine 123 fluorescence are similar if mitochondria are rendered chemically anoxic with CN in lieu of absence of oxygen, shown in Fig. 1J. Notably, rotenone conferred a CAT-induced depolarization when added after CN (compare trace b, with trace a, in Fig. 1J); as it will be shown later on, this reflects that NAD+ provision to OgDHC by residual CI activity is critical for maintenance of ANT operation in ‘forward’ mode12. The effect of CN (or azide) on Q redox state cannot be investigated with the Q-sensor because of direct interference with the electrode17. The rotenone-induced increases in reduced Q and NADH suggest that CI was operating in forward mode; although CI is fully reversible 33,34 the conditions allowing reversibility in organello are extreme: by plotting CI forward- vs reverse operation as a function of UQH2/UQ, NAD+/NADH, matrix pH (pHin) and ΔpH across the inner mitochondrial membrane and assuming that anoxia clamps ΔΨmt of isolated mouse liver mitochondria to ~ − 100 mV35, there can be only two circumstances upon which CI may operate in reverse: as shown in supplementary Fig. 6, CI operates in reverse if either (i) UQH2/UQ > 100 an NAD+/NADH = 10 and pHin 7.35 and ΔpH is between 0.8 and 1.0 (supplementary Fig. 6D), or if (ii) UQH2/UQ > 100 and NAD+/NADH = 10 and pHin 8.35 and ΔpH is between 0.5 and 0.8 (supplementary Fig. 6E). Alternatively, these values could reach more realistic numbers if mitochondria became more polarized during anoxia (delineated by the dotted areas in the same panels), which on the other hand, is extremely unlikely. Overall, it is impossible to achieve such conditions in intact mitochondria. Finally, as shown in supplementary Fig. 1A and supplementary Fig. 3A (bottom panels) inhibition of the adenine nucleotide translocase (ANT) by carboxyatractyloside (CAT) in rotenone-inhibited, but not anoxic mitochondria leads to a gain in ΔΨmt, commensurate with our previous data showing that ANT remains in forward mode when CI is inhibited12. Likewise, addition of CAT to anoxic mitochondria (in the absence of rotenone, supplementary Figs. 1B and 3B, bottom panels) also leads to a gain in ΔΨmt, commensurate to our data published before35. However, CAT led to a loss of ΔΨmt when CI was inhibited in anoxic mitochondria (Fig. 1C and supplementary Fig. 3C, bottom panels), implying ANT reversal36. The observation that the ANT was operating in forward mode when oxygen was absent (or CIV was inhibited by CN) or CI was inhibited, and in reverse mode when both oxygen was absent and rotenone was added (see also Fig. 1J regarding chemical anoxia) hints that rotenone affects mtSLP, the primary determinant of ANT directionality when OXPHOS is inhibited37. Alternatively, rotenone could have an off-target effect anywhere on pathways converging towards mtSLP, dictating ANT directionality. However, the alternative CI inhibitors pyridaben (Prdb) and piericidin A (Pierc) reproduced the effect of rotenone on Q redox state during anoxia (see representative traces in supplementary Fig. 3D, E, middle panels; mean signals are shown in supplementary Fig. 1C). Accordingly, a further increase in NADH autofluorescence was observed when CI inhibitors were added during anoxia (supplementary Fig. 3F, G, middle panels; mean signals shown in supplementary Fig. 1F). It is noteworthy that the effect of the inhibitors on the Q signal was unequal (strength of effect, in descending order: rotenone > pyridaben > piericidin A), while all three exerted the same effect in increasing NADH autofluorescence when added on top of anoxia. This probably reflects that although rotenone, pyridaben and piericidin A share a common binding domain at- or in the vicinity of the UQ reduction site38, the exact sites of action can be more than one in addition to being partially overlapping39. Nonetheless, addition of Prdb or Pierc during anoxia led to a CAT-induced loss of ΔΨmt, implying ANT reversal and therefore absence of mtSLP (supplementary Fig. 3D–G lower panels). As expected, the Complex II inhibitor atpenin A5 (Atpn) also led to a CAT-induced loss of ΔΨmt, implying ANT reversal and therefore absence of mtSLP (supplementary Fig. 3H). The lack of effect on these (and all other inhibitors used in this study) on inducing permeability transition during anoxia (detected by changes in light scatter of the organelles) is shown in supplementary Fig. 7A. The potential connection of CI activity to mtSLP is provision of NAD+ for OgDHC which yields succinyl-CoA, in turn supporting mtSLP40. Because the rotenone-induced changes in NADH fluorescence and Q redox state in anoxia were smaller than those conferred in the presence of oxygen (compare Fig. 1E with supplementary Fig. 1D for NADH and Fig. 1C with supplementary Fig. 1A, middle panels for UQ), we deduced that CI activity is only partially active during anoxia. To further support our claim, we measured the total amount of NADH that could be extracted from mitochondria during OXPHOS respiration, after anoxia, and after addition of rotenone in anoxia. As shown in figure panel 1G, anoxia led to an increase in the total amount of NADH compared to OXPHOS (grey bar); further addition of rotenone (blue bar, Rot) led to a further increase in NADH, which is small compared to the anoxic state, mindful that the rotenone-induced increase in NADH fluorescence in anoxic, intact mitochondria is fairly small (see Fig. 1 panel E), in addition to the notion that total amount of NADH is subject not only to oxidation mediated by CI, but other matrix entities as well, see supplementary Table 1.
To address the possibility that the Oroboros chamber and/or the 3D-printed plug (used for experiments shown in supplementary Fig. 7 with standard polymethacrylate cuvettes) where true anoxia was implied but not actually achieved due to potential leakage of gases through the pins through which the Q electrode and chemicals are added, we manufactured air-tight borosilicate glass chambers. These chambers consist of a chamber and a glass lid and in-between a PTFE/Silicone septum (Supelco, 27095-U) is in place that exhibits severely limited oxygen permeability (appreciable diffusion of oxygen and other gases through these septa occurs within weeks, much longer than the time frame of our experiments that lasted 10–20 min). This septum can be pierced by Hamilton syringes and self-seals immediately upon retrieval of the syringe. Piercing and self-sealing can be reliably applied at least four times per septum. Schematics and pictures of such a chamber are shown in supplementary Fig. 2A–G. All chemicals injected through the septum are gassed with Argon 5.0 (99,999% pure). Borosilicate glass of the chamber prevents near-UV light (required for NADH fluorescence measurements) only to a minor extent; NADH spectra for a polymethacrylate cuvette (suitable for UV) and for the glass chamber are shown in supplementary Fig. 2H and supplementary Fig. 2I, respectively. A far-left shoulder of NADH excitation (black trace, supplementary Fig. 2H, around 260 nm) is eliminated when the NADH spectrum is performed in the glass chamber (supplementary Fig. 2I), but that did not affect our measurements because excitation was set to 340 ± 5 nm where less than 10% loss was observed in the exc/em peaks. Rhodamine 123 fluorescence was completely unaffected; as shown in supplementary Fig. 2J, rhodamine 123 fluorescence exhibited an abrupt splay towards higher values (implying depolarization), which is expected upon commencement of anoxia. Subsequent addition of CAT in the presence (blue trace, b) but not in the absence (black trace, a) of rotenone led to a further depolarization, exactly in line with the notion that ANT remains in forward mode when CI is not pharmacologically inhibited12. Likewise, addition of rotenone in anoxic mitochondria led to an increase in NADH fluorescence (supplementary Fig. 2L) compare to vehicle (supplementary Fig. 2K). Since the traces obtained from mitochondria suspended in the air-tight glass chamber (rhodamine fluorescence, NADH fluorescence and response to all inhibitors and treatments) were almost identical to those obtained with the Oroboros chamber, we were confident that no minor oxygen leakage was occurring in the latter instrument, where Q redox state can be also addressed; thus, our interpretations were not confounded from a potential oxygen leakage. Accordingly, the presence of CIII inhibitor myxothiazol did not prevent the rotenone-induced increase in NADH fluorescence (supplementary Fig. 2M), but addition of 5 mM succinate (S) prior to rotenone completely prevented this effect (supplementary Fig. 2N). This hinted to the potential role of Complex II operating in reverse (and thus prevented from doing so by excess succinate), providing UQ to a residually-operating CI, as suggested in41. Quantification of technical replicates is shown in a bar graph in supplementary Fig. 2O, P. Fumarate is a very poor substrate (largely due to slow uptake) in isolated mitochondria; experiments where the ratio of succinate/fumarate was experimentally altered using permeabilized mitochondria is addressed below (see supplementary Fig. 10). The effects of rotenone conferring a CAT-induced depolarization in anoxic mitochondria concomitant to a rotenone-induced increase in NADH fluorescence was also observed in intact mitochondria obtained from brains (supplementary Fig. 4) and hearts of mice (supplementary Fig. 5).
Endogenous Q pool is rapidly declining, supporting a brief, partial CI activity during acute anoxia
NADH availability could not have been a factor of finiteness as it is in excess during the anoxic insult. On the other hand, mindful that the amount of CI in rodent liver is ~ 6 pmol/mg protein42, the total CoQ content is higher than 3 nmol/mg43,44, the amount of CoQ bound to mitochondrial proteins is between 10 and 32%45, CoQ binds stoichiometrically with each site in the ETS complexes46–48, and the catalytic turnover of CI is 104/min42,49 it should take only a few seconds for Complex I to reduce all available CoQ. To address the ETS-reactive pool of Q supporting CI activity during anoxia we recorded the % change in the Q signal as a function of time elapsed from commencement of anoxia until the addition of CI inhibitors. As shown in supplementary Fig. 9, rotenone (A–C) or pyridaben (D) or piericidin A (E) was the CI inhibitor when using either glutamate (G) and malate (M), or oxoglutarate (Og), or oxoglutarate and malate as fueling substrates. Representative experiments used to estimate Q % redox states as a function of CI inhibitor and/or substrate(s) are shown in supplementary Fig. 8 panels A-G, middle panels. It is evident that the longer the time elapsed from commencement of anoxia until addition of CI inhibitors the smaller the relative change of the Q signal. During anoxia the ability of permeabilized mitochondria (using alamethicin) to oxidize exogenous NADH in a rotenone-sensitive manner is decreasing in a time-dependent manner, see supplementary Fig. 9F, G. As expected, CAT induced loss of ΔΨmt in all conditions irrespective of inhibitor or substrate(s) present or time elapsed, implying ANT reversal (supplementary Fig. 8A–G, bottom panels). The discrepancy between the fact that the amount of reducible CoQ is sufficient for only a few seconds with the extended time frames observed in our experiments shown in supplementary Figs. 8 and 9 cannot be reconciliated.
To address this further, we fed mice with a diet devoid of vitamin K3 over the course of approximately 3 weeks. Omission of vitamin K3/K1 from the diet has been reported to influence the mitochondrial Q/menaquinones pool in laboratory rodents respectively50,51. After each week, prothrombin time (PT) was measured as an indicator of vitamin K status52–54. As shown in supplementary Fig. 8H, PT was increased in mice kept in vitamin K3-deficient diet. In post-day 16 after implementing the vitamin K3-deficient diet total liver Q levels were diminished, see supplementary Fig. 8I; however, by post-day 24 the trend was reversed, which means the dietary intervention did not affect CoQ content. The Q redox state upon addition of rotenone did not differ in anoxic mitochondria obtained from mice kept on vitamin K3-deficient diet for 3 weeks vs control littermates (supplementary Fig. 8J). Although it is possible to use transgenic mice with constitutive ablations in genes coding for proteins participating in the ubiquinone synthesis pathway, such mitochondria would inherently exhibit severe OXPHOS deficiencies to the point that ANT directionality could not be addressed, since such assays require fully polarized mitochondria with very high respiratory control ratios37. Despite that we could not manipulate the pool of endogenous CoQ by dietary means, the data above support the notion that UQ availability is critical for CI activity during anoxia only for a few seconds. However, this does not exclude the possibility of UQH2 also being simultaneously oxidized by some other entity during anoxia. We have also addressed the possibility that the mitochondrial transhydrogenase (encoded by NNT) may have some contribution to NADH/NAD+ ratio and as an extension of this to UQ/UQH2; for this, we compared liver mitochondria isolated from C57Bl/6N mice vs those obtained from the 6J sub-strain; mice of the latter strain do not exhibit the transhydrogenase55. The latter effect may bear relevance to our study because in light of a disability to form respiratory complexes, sources of electron for the ETS may come from elsewhere. However, as shown in supplementary figure panels 8K and 8L for Q oxidation (%) and NADH %, respectively, there were no statistically significant differences between the results obtained from rotenone added to anoxic mitochondria isolated from the livers of 6N (smooth) vs 6J (cross-hatched) mice. Thus, the only potential source of UQ to CI could be from CII reversal, see below.
Fumarate reductase activity in permeabilized mitochondria
The concept of combined Complex I activity in forward mode and Complex II in the reverse collectively referred to as “NADH:fumarate reductase activity” originates from Sanadi and Fluharty56. However, mindful that this activity is ~ 100 times smaller than the physiological NADH:Q10 reaction of Complex I49, we set to estimate the activity of CII reversal in permeabilized mitochondria, as this is imperative for the overall NADH:fumarate reductase activity to manifest. The experimental protocol was to evaluate the rate of rotenone-sensitive NADH oxidation activity in permeabilized mitochondria that were rendered anoxic, and variate the fumarate/succinate (Fum/Succ) ratio. Anoxia was applied as either ‘true’ by allowing mitochondria to run out of oxygen in the air-tight glass chambers or ‘chemical’ by inclusion of KCN. Permeabilization was achieved by adding the pore-forming peptide alamethicin to the media. Representative traces for KCN-induced anoxia and NADH oxidation rate is shown in supplementary Fig. 10A, and for true anoxia in supplementary Fig. 10C. As shown in supplementary Fig. 10B and 10D for KCN and true anoxia respectively, we were unable to demonstrate a statistically significant tendency in which greater concentrations of fumarate ‘pushing’ CII towards higher reversal rates would yield greater rates of NADH oxidation by CI (by means of providing more UQ). This is not surprising, considering the very low rate at which CII reverses. Indeed, as Spinelli has shown41, CII reversal by addition of fumarate to respiration-impaired mitochondria can only be observed upon very long incubation periods (see Fig. 2 panel I on the right in reference41). There, it was necessary to wait several hours, until the rate of succinate produced by CII reversal could be reliably detected. However, it is not necessary to have a high rate of CII reversal in order for CI to provide a sufficient amount of NAD+ for OgDHC; it is emphasized that the main point of the present work is to demonstrate provision of ATP from succinate-CoA ligase for maintaining ANT in forward mode, during anoxia; that requires succinyl-CoA which comes from OgDHC. These are addressed in subsequent sections (Figs. 4 and 5), but prior to that we investigated the potential contribution of CIII as a means of UQH2 oxidizer, when CIV is not operational.
CIII does not affect CI operation during anoxia to an appreciable extent
Having established that CI exhibits residual activity even in anoxia (true, or chemical) thus reducing UQ to UQH2 and mindful that the latter is the substrate of CIII, we tested the effect of CIII inhibitor myxothiazol (Myx, Fig. 2A) on Q- and NADH/NAD+ redox levels. As shown in Fig. 2 panel B, the presence of myxothiazol led to a minor though statistically significant decrease in UQH2 oxidation levels when added in anoxia, reflecting a minor CIII activity. This change was enhanced by addition of rotenone prior to myxothiazol (both added after anoxia, Fig. 2C), but UQH2 levels were higher implying that in anoxia the changes in Q pool are mostly dictated by CI and not CIII. The effect of rotenone when added after myxothiazol still implied residual CI activity even with CIII already inhibited; the effects of the alternative CI inhibitors pyridaben and piericidin A are shown in supplementary Fig. 11A. Similarly, the presence of myxothiazol before (Fig. 2D) or after (Fig. 2E) rotenone (and supplementary Fig. 11B for pyridaben and piericidin A) did not abolish NADH changes conferred by the CI inhibitors. These results argue that in anoxia there is a minor CIII activity, but most importantly CI residual activity is not solely influenced by inhibition of CIII. The electron acceptor(s) for this minor CIII activity were not investigated further.
CII operates amphidirectionally, reducing fumarate during acute anoxia
Spinelli et al. reported that in hypoxia or in cells genetically modified to lack CIII or CIV, alterations in the UQH2/UQ ratio support the reverse operation of CII, and as a consequence of this, CI remains partially operational41. However, for the reasons reviewed in57, the reverse operation of CII is unfavored, although not precluded. In the same line of thought, the group of Brookes reported that in cardiac ischemia, succinate accumulates mostly through canonical Krebs cycle activity through which the oxidative decarboxylation of 2-oxoglutarate produced from glutamine also takes place5. However, they did also report that CII was also operating in reverse, albeit to a moderate extent. The conundrum of whether CII operates in forward or reverse is relevant to the present study, because the reverse operation of CII yielding UQ would essentially be the means for maintaining CI operation forming UQH2, especially in view of the fact that endogenous UQ pools may last only for a few seconds. We therefore examined the effect of CII inhibitors atpenin A5 (Atpn) and malonate (Mna) (Fig. 3A) added before or after the addition of CI inhibitors during anoxia, and measured the Q and NADH/NAD+ redox states. As shown in Fig. 3 panel B (representative trace; mean data shown in figure panel 3D and supplementary Fig. 12 panel A), addition of rotenone after any CII inhibitor in mitochondria that were previously respiring on glutamate and malate (5 mM, each) led to a greater increase in UQ implying a greater inhibition of UQ reduction than addition of CI inhibitor alone (marked by a blue dash line traversing Fig. 3D–F), in addition to conferring an increase in NADH depicted in figure panels 3G; furthermore, addition of any CII inhibitor alone during anoxia did not lead to a statistically significant increase in UQH2/UQ compared to vehicle. However, addition of malonate (but not atpenin A5) during anoxia led to an increase in NADH autofluorescence, see figure panel 3G. Addition of atpenin A5 after rotenone led to a greater increase in UQ, implying a greater inhibition of UQ reduction (Fig. 3E). Addition of atpenin A5 after rotenone did not lead to a statistically significant change in NADH levels during anoxia, confirming that when CI is inhibited the contribution of CII to matrix NADH levels is irrelevant, see Fig. 3H. Note that while both CI and CII operate in the direction of UQH2 formation, this is not masked by a potential concomitant CIII operation, oxidizing UQH2 to UQ; indeed, as shown in Fig. 3C (representative trace; mean data shown in figure panel 3F), the presence of the CIII inhibitor myxothiazol led to a decrease in UQ in the combined presence of rotenone and atpenin A5, implying diminished availability of UQ from CIII to CI and CII; similarly, the same can be observed in NADH levels (Fig. 3I), meaning that UQ arising from CIII would be used by CI and CII. Qualitatively similar findings were observed with the alternative CI inhibitors piericidin A and pyridaben shown in supplementary Fig. 12 A–F. Collectively, the data suggest that in acute anoxia, CII operates in the direction of UQH2 formation. However, these data do not argue that CII operates exclusively in forward mode. To address the directionality of CII during acute anoxia, we examined the effect of metabolites passing through CII by measuring Q and NADH/NAD+ redox states while pharmacologically inhibiting specific complexes shown in Fig. 4A. As shown in Fig. 4B, addition of succinate (S) after rotenone leads to UQ reduction under anoxia, implying that CII can still operate in forward mode. In Fig. 4C, addition of succinate before rotenone in anoxic mitochondria depicts less inhibition of UQH2 formation than rotenone alone (Fig. 4B), implying that succinate was impairing CI operation during anoxia. This effect of succinate was abolished by atpenin A5 (Fig. 4D). Addition of rotenone during anoxia led to an increase in NADH levels which was mitigated by the subsequent addition of succinate (Fig. 4E). Addition of rotenone after succinate during anoxia still led to an increase in NADH levels implying that CI remained operational (Fig. 4F). However, the increase in NADH levels is smaller in the presence of exogenously added succinate than in its absence (see blue dash line traversing Fig. 4E–G). Likewise, atpenin A5 abolished the effect of succinate on rotenone-induced changes on NADH levels (see Fig. 4G). Similar effects were obtained by replacing rotenone with the alternative CI inhibitors, piericidin A and pyridaben (supplementary Fig. 12G, H). These data reiterate that CII operates in forward mode in the very short initial time interval and this hinders CI’s ability to produce NAD+. Finally, the effect of exogenous addition of succinate in the presence of rotenone yielding a decrease in NADH levels could be interpreted by considering that CII was also operating in reverse, reducing fumarate to succinate; as such, it would generate UQ for CI and maintain a residual operation. Overwhelming the system with succinate, would mitigate this effect. This is further addressed in the subsequent section, see Fig. 5.
Next, to corroborate the finding that during acute anoxia CII operates in the direction towards succinate oxidation forming UQH2, we performed untargeted analysis of pertinent metabolites while ETS components where pharmacologically inhibited. Mitochondria were allowed to respire on glutamate and malate in the presence of ADP to the point of O2 depletion from their suspending medium. This was verified by monitoring O2 concentration polarographically. As shown in Fig. 4H, anoxia increases the concentration of succinate while rotenone partially abolished this. Quantification of other untargeted metabolites is shown in the supplementary Fig. 13. On the other hand, atpenin A5 not only fails to diminish succinate concentration, it even potentiates the increase. This means that during anoxia (i) CII was operating in the direction of succinate oxidation (i.e. forward mode) and that (ii) CI operation was supporting succinate formation. However, this does not exclude the possibility of CII reversal at a later time, as hypothesized above. To address this, we performed experiments on isolated mitochondria in which [U-13C]glutamate was added just before the onset of anoxia (when [O2] was ~ 10 μM) and collected them at three different time points indicated as extraction point (E.P.) 1, 2, and 3 corresponding to 76 s, + 200 s and + 400 s post-anoxia in figure panel 4I followed by quantification of selected metabolites, including 13C-labelled succinate. We compiled these data in a simple model in which succinate may originate from OgDHC (from 2-oxoglutarate through succinyl-CoA) or through CII reversal (from fumarate), also acknowledging a certain loss of succinate by being transported out of the matrix, depicted in figure panel 4J. The model can be formulated as:
where ΔkS is the total change in succinate amount of the k isotopologue; ΔSG, ΔSM, ΔST are the amounts of succinate coming from the direction of glutamate (through 2-oxoglutarate), malate (through fumarate) and transport across the inner mitochondrial membrane (IMM) respectively; xG,k, xF,k, xS,k are the amount fractions of the k isotopologue for 2-oxoglutarate, fumarate and succinate respectively. Under k isotopologue we refer to either unlabeled (M + 0) or fully labelled (M + 5 for 2-oxoglutarate) and (M + 4 for succinate and fumarate) substances. Especially the amount fractions of 2-oxoglutarate isotopologues showed a marked change as a function of time (supplementary Fig. 14 panels A, B). To estimate the averages, we fitted an exponential and calculated the means of the functions using the coefficients of the fits. It is evident that regardless of the presence of atpenin with (blue dots) or without oligomycin (red dots) the end points of the amount fractions are nearly the same, thus it is safe to assume that the average amount fractions are nearly the same in the presence of the inhibitors as well. When atpenin A5 is present, CII is expected to be completely inhibited without affecting the rate of transport and thus we can solve for ΔST and ΔSG using the above model (results shown in supplementary Fig. 14 panel E). Using this ΔST in the absence of atpenin A5 we solved for ΔSG and ΔSM (shown in Fig. 4 panel K) to obtain the average contribution of each pathway over the initial post-anoxic 600 s period. Seeing that the changes in matrix succinate concentration are fairly small (in arbitrary units 63.6 at 0 s, 68.8 at 200 s and 85.7 at 600 s), we assumed that this would not affect the rate of succinate transport across the IMM to a great extent, thus, we could extrapolate its value to individual time periods. This allows us to break down the gross 600 s period (Fig. 4 panel K) into constituent initial 200 s (Fig. 4 panel L) and following 400 s (Fig. 4 panel M) periods evaluated similarly. The results show that the relative contributions to succinate accumulation changes over time, from an initial OgDHC dominance (Fig. 4 panel L) to a CII reversal dominance (Fig. 4 panel M). To state this more simply, at the beginning of anoxia succinate was mostly produced using carbon atoms from glutamate, but over time succinate originates increasingly from fumarate.
Oxidation of NADH by CI supports OgDHC, in turn maintaining the oxidative decarboxylation pathway from glutamate
To address the possibility that CI favored the formation of succinate through supporting the oxidative decarboxylation of 2-oxoglutarate at the onset of anoxia, we performed the untargeted metabolite analysis in the presence of arsenite (Arsn, HAsO32−, see Fig. 5A) and other ETS inhibitors. When using glutamate plus malate as substrates, the only target of arsenite is OgDHC, if the variable to be measured is succinate concentration; glutamate dehydrogenase is not sensitive to arsenite58. Indeed, as shown in Fig. 5B, arsenite abolished the increase in succinate, irrespective of the presence of rotenone or atpenin A5. This means that succinate originated from the canonical Krebs pathway: glutamate → 2-oxoglutarate → succinyl-CoA → succinate. However, it does not mean that during anoxia, succinate originated exclusively from this metabolic branch, and as shown above, the contribution of succinate from CII reversal is increasing over time, while endogenous Q pools are depleted; to address this further, we traced metabolites harboring 13C that could originate from [U-13C]glutamate or [U-13C]malate. As shown in Fig. 5C, during anoxia the abundance of labelled succinate in mitochondria that were exogenously given [U-13C]glutamate is lower when rotenone was present; atpenin A5 increased the amount of labelled succinate, while arsenite decreased the abundance of succinate labelling, compared to its absence. The data obtained from 13C metabolic tracer analysis using [U-13C]glutamate agree with the untargeted metabolite analysis arguing that succinate originated from the canonical Krebs pathway, depicted in Fig. 5D. It is noteworthy that in the presence of atpenin A5, while succinate is building up significantly, it is unable to exit mitochondria as easily as under other conditions (ratio of pellet to supernatant is significantly altered). The reason(s) behind this could be due to enhanced malate uptake or excretion of another dicarboxylate, effectively out-competing succinate; alternatively, this could be a result of issues co-transporting inorganic phosphate (Pi): the dicarboxylate transporter can exchange a dicarboxylate for Pi59, so when Pi builds up in the matrix (due to extensive ATP hydrolysis by a reverse-operating F1FO-ATPase35) the exchange for succinate could be inhibited, hence malate enters against citrate and the dicarboxylate carrier is effectively fully inhibited. By inhibiting ATP hydrolysis with oligomycin, succinate export was affected but not to a significant extent (supplementary figure panel 14F), although this could be confounded by other factor(s), such as depolarization of mitochondria. This line of thought was not pursued further. The abundance of other targeted metabolites is shown in supplementary Fig. 15. There, the ~ 5-fold increase of oxoglutarate from [U-13C]glutamate by arsenite indicates genuine inhibition of the oxoglutarate Complex. Results on labeled fumarate also confirm that while fumarate hydratase is working at equilibrium loading the pool from unlabeled malate, contribution from glutamate is significantly reduced after addition of rotenone, atpenin A5 and arsenite. The reduction after rotenone is similar to that of succinate, showing the reduction is upstream, as opposed to the presence of atpenin A5. However, when using [U-13C]malate, there was succinate labelling during anoxia (Fig. 5E) but with no labelling of oxoglutarate (supplementary Fig. 16A). This could only mean that CII was also operating in reverse to some extent, depicted in Fig. 5F, and consistent with the notion that most of the citrate being produced is being exported against the malate gradient, essentially reinforcing the conclusions obtained from the data and model shown in figure panels 4I-4M. The abundance of other metabolites that acquired labelling from [U-13C]malate is shown in supplementary Fig. 15. Regarding Fig. 5D, F even though the reaction catalyzing the interconversion of malate to oxaloacetate by malate dehydrogenase is definitely occurring as evidenced by the aspartate labeling, oxaloacetate is omitted as we could not detect it. In Fig. 5D, F we only mark metabolites outlining the metabolic routes taken, and not all metabolites detected with the 13C labels, for clarity.
So how can it be that CII operates amphidirectionally? The reaction catalyzed by CII is succinate + UQ ↔ fumarate + UQH2; however, there are other reactions affecting each reactant as well: succinate is also influenced by succinyl-CoA ligase, fumarate by fumarase, UQ and UQH2 by CI and other enzymes converging at the mitochondrial coenzyme Q junction30,31. By plotting succinate/fumarate ratio (on the basis of metabolite content in the pellets during anoxia, obtained from the targeted 13C metabolic tracer analysis) vs UQ/UQH2 ratio, it is apparent that CII directionality is dictated by the pair of values across a straight line, see Fig. 5G. However, fumarase, CI, and enzymes converging at the mitochondrial Q junction (as well as other enzymes having succinate or fumarate as substrates or products, see https://metabolicatlas.org/explore/Mouse-GEM/gem-browser/metabolite/MAM02943m and https://metabolicatlas.org/explore/Mouse-GEM/gem-browser/metabolite/MAM01862m, respectively) will lead to a shifting pattern of succinate/fumarate and UQ/UQH2 pair values across this line, which means that the direction favored by CII will be changing as dictated by the very same value pairs. In addition, since UQ may be protein-bound or unbound to the extent of 10–32%45 the amount of protein-unbound UQ and the parameters influencing this binding (such as the lipophilicity property of the UQ type60–62) will also dictate CII directionality.
Mindful that succinate may arise from either (i) glutamate → 2-oxoglutarate → succinyl-CoA → succinate and/or (ii) reduction of fumarate implying CII reversal, the question arises which pathway contributes more significantly to altering succinate concentration in the matrix during acute anoxia. To this end, we titrated the amount of exogenously added succinate in reversing ANT directionality during anoxia; the rationale of this approach is that if CII reversal is considerable, the amount of succinate generated should inhibit the ATP-forming mtSLP which dictates ANT directionality12. As shown in supplementary Fig. 16B the concentration of exogenously added succinate for causing CAT-induced delayed loss of ΔΨmt after anoxia is in the order of 0.5–2 mM (left three panels). The Km of the dicarboxylate transporter translocating succinate across the mitochondrial inner membrane is > 1.1 mM63. Accumulation of succinate in the matrix is also dependent on ΔΨmt; the more depolarized mitochondria are, the less succinate is taken up64. It is therefore reasonable to assume that addition of 0.5 mM succinate to already depolarized mitochondria due to anoxia leads to a small increase in matrix succinate concentration, well below 0.5 mM. As this is a small amount, we conclude that CII could not operate in reverse to an appreciable degree during the very first moments of acute anoxia, as the amount of succinate formed is insufficient to hinder mtSLP. Furthermore, exogenously added 0.5 mM succinate still yielded UQ reduction to UQH2, implying that CII was mostly operating in forward mode (figure supplementary Fig. 16B, rightmost panel). However, as the endogenous Q pools become rapidly reduced over time commencing from the post-anoxic event, the contribution of succinate from CII reversal becomes more and more significant, for as long as the Q pools are not re-oxidized.
Finally, in view of the proposal that hypoxia modulates respiratory chain supercomplex formation resulting in the stabilization of these supramolecular structures65,66, we tested whether conditions of acute anoxia had an impact on the stability of Complex I and on the formation of supercomplexes. The isolated mitochondria that were either kept in normoxia or subjected to acute anoxia with or without inhibitor treatments were solubilized using digitonin, a detergent that maintains the interaction between the complexes, and run through Blue-Native Gel Electrophoresis (BNGE). As shown in Fig. 6, the immunodetection of Complex I revealed no major changes either in supercomplex distribution or in the levels of any of the Complex I-containing species (free Complex I and supercomplexes I + III2 and I + III2 + IV–respirasomes) induced by acute anoxia using NDUFS1- and SDHB antibody for complexes I and II, respectively. This was tested not only in liver mitochondria from C57Bl/6J mice, which due to the absence of a functional Cox7a2l showing a different supercomplex pattern67,68 but also in mitochondria from the 129/Sv mouse strain in which all the supercomplex species can assemble.
Discussion
It is a textbook definition, that -except in animal species adapted to prolonged survival under anoxia69—in the absence of oxygen there is no electron transport in the mitochondrial respiratory chain, the Krebs cycle is inhibited, and there is accumulation of reducing equivalents in the mitochondrial matrix. However, the catabolism of glutamine by the oxidative decarboxylation route entering the Krebs cycle during hypoxia has been unequivocally demonstrated5,35,70,71; the significance of this echoes the need for addressing the reductive stress when combating diseases spanning from ischemia–reperfusion to cancer4. What has not been fully addressed is the origin of NAD+ for supporting OgDHC in the pathway glutamine → glutamate → 2-oxoglutarate → succinyl-CoA → succinate, for the 2-oxoglutarate to succinyl-CoA conversion during anoxia. To this end, various potential sources have been theorized to contribute72, including CI. Indeed, in cells experiencing hypoxia (1% O2) or genetically engineered to lack key components of either Complex IV (CIV) or Complex III (CIII) rendering them incapable of using O2 as a terminal electron acceptor, CI was still able to deposit electrons into the ETS41. The experiments of Spinelli et al. on generating such cell lines was instrumental in addressing the concept that CIV exhibits a sufficiently high affinity for O2 that could maintain full activity even in 1% O273. Spinelli et al.41 proved that under such conditions succinate dehydrogenase (CII) was operating in reverse reducing fumarate, supported by the high UQH2/UQ ratio. In their work41, residual activity of CI in hypoxia or in cells lacking CIII or CIV was implied, something that has been previously proposed as plausible by mathematical modelling, even in anoxia72. On the same line of thought, the group of Finch showed that NAD+ originating from the reverse operation of the mitochondrial malate dehydrogenase isoform 2 (MDH2) support glutamate dehydrogenase (GDH) activity, fulfilling anaplerosis in respiration-deficient cells74. Likewise, the group of Tennant showed that in hypoxic conditions mitochondrial pyrroline 5-carboxylate reductase 1 (PYCR1) activity is increased yielding NAD+, permitting continued TCA cycle activity in vivo and in 3D cultures75.
The most important finding of the present study is that during anoxia CI remains operational, albeit to a diminished, but sufficient extent for supporting the reaction catalyzed by OgDHC with NAD+. The significance of this finding has the following four ramifications:
-
(i)
It can explain earlier findings reporting that CI inhibitors yield less succinate when added in hypoxic tissues 5,76,77. The accumulation of succinate in ischemia is unquestionable 78–81, however, its origin is debated; on one hand, CII reversal reducing fumarate to succinate yielding UQ for CI has been convincingly demonstrated 41,78; on the other, succinate formation by the oxidative deamination of glutamine/glutamate and following canonical Krebs cycle activity has been shown to be quantitatively more important 5. Here we show that during the anoxic event CII was functional and its directionality changed from forward to reverse, most likely due to the rapidly declining sources of endogenous quinones. In either case -CII reversal yielding succinate from fumarate or CII forward diverting UQ away from CI- CI remains operational in anoxia, providing OgDHC with NAD+. Relevant to this, the finding that CII reversal is critical for maintenance of CI operation could explain our earlier findings on comparing the effect of 2-oxoglutarate in the presence and absence of malate, on mtSLP during either CI inhibition by rotenone vs in anoxia 82. As shown in supplementary Fig. 18 (reproduced by permission; it is an excerpt of Fig. 5 of reference 82) the presence of malate (when 2-oxoglutarate is already present) is able to rescue mtSLP in anoxic mitochondria, i.e. 2-oxoglutarate alone is not sufficient. This is because malate is able to follow the route of malate → fumarate → succinate. The latter part of this pathway entails CII in reverse, providing UQ (from UQH2) to CI, which generates NAD+, donates it to OgDHC and mtSLP is maintained. Of note, malate becoming oxaloacetate could not be the reason for this rescue, because: (i) when respiratory chain is deficient, the mitochondrial malate dehydrogenase 2 operates in reverse, oxidizing NADH 74 and (ii) oxaloacetate would inhibit succinate dehydrogenase that in turn would disfavor CII reversal. The ability of the tissue to withstand anoxia will eventually depend on the availability of Q pools for the acute phase (for a few seconds) and the availability of fumarate (which could originate from malate) for the latent phase. Fumarate supporting CI and in extension of this both ΔΨmt 83 and provision of NAD+ to OgDHC (this study) could arise from aspartate through the concerted action of purine nucleotide cycle and aspartate aminotransferase 78. However, there are two concerns with this concept: first, the purine nucleotide cycle is an energy-dependent process 84; second, the energy provided by CI could not be in the form of ΔΨmt to a sufficient extent: acknowledging that CI activity in anoxia is ~ 10% of its theoretical maximum and mindful that only 4 protons are pumped out of the 4 + 4 + 2 for CI, CIII and CIV, respectively by the ETS and that ΔΨmt fluctuates between −108 and −158 mV in normoxia 85 and is clamped to ~ −100 mV in anoxia35, the contribution of CI to generating membrane potential in anoxia should be a meager 2.5—3.7 mV, which is reflected in our rhodamine 123 recordings, given the evanescent changes in fluorescence. Thus, it is likely that the availability of UQ for CI for the acute phase shown hereby may generate sufficient UQH2 that can support CII reversal in the latent phase.
-
(ii)
Oxidation of UQH2 in mitochondria is necessary for tumor growth 86, where oxygen availability is frequently limited 87: it is extremely likely that NADH oxidation by CI requiring UQ in hypoxia is the missing link for providing NAD+ to OgDHC supporting the oxidative decarboxylation branch of glutaminolysis; glutaminolysis is a hallmark of many cancers 88. Indeed, the group of Chandel 86 demonstrated that the loss of CI thwarted tumor growth and this was rescued by mitochondrially-targeted expression of the NADH oxidase LbNOX 89.
-
(iii)
Relevant to the results published in 86, the role of CI in the proliferation of cancer cells has been reviewed in 90, and the consensus was that a complete- as opposed to an incomplete- loss of CI activity halts tumor growth, although avoidance of reactive oxygen species (ROS) generation was proposed to mediate this effect. In addition, CI inhibitors exhibiting potency against solid cancers in murine models and human cell lines are being evaluated in > 400 clinical trials 91.
-
(iv)
CI has been described to exist in two forms, an active (A) and a de-active (D) form, the latter signifying a dormant state of the complex which is not inactivated or covalently modified in any way 92; the A to D transition occurs during ischemia, i.e. when substrate and oxygen availability are limited 93. The D form is thought to exert a protective role by delaying the rate of regaining normal respiration rates during reoxygenation, thus potentially mitigating ROS production 94; the other side of the coin is that when in D form, CI risks becoming permanently inactive 95. Although it is not possible to decipher if residual CI activity maintained by UQ availability during acute anoxia will be beneficial or not regarding ROS formation vs risk of permanent inactivation, it certainly influences the A to D transition phenomenon.
A common denominator of the above is that subsequent catabolism of succinyl-CoA, the product of OgDHC which is supported with NAD+ provided by residual CI activity during anoxia will contribute to mtSLP. The generation of high-energy nucleotides by mtSLP has been unjustly side-lined in the literature; it is true that the rate of ATP (or GTP, depending on subunit composition of the succinyl-CoA ligase and the presence of a nucleoside diphosphokinase96,97) synthesis dwarfs compared to that by the mitochondrial F1FO-ATPase. However, during anoxia the F1FO-ATPase is hydrolyzing ATP instead of producing it98; in this case, the amount of ATP produced by mtSLP in combination to the much smaller volume of mitochondrial network compared to that of the cytosol amplifies the effects of ATP production in terms of concentration. This could rescue a tissue experiencing respiratory inhibition by preventing mitochondria from becoming ATP drains36.
In conclusion, we hereby showed that in isolated murine mitochondria experiencing anoxia, CI exhibits sufficient activity yielding NAD+ for OgDHC that in turn forms succinyl-CoA supporting mtSLP; the availability of UQ is a critical factor for this residual CI activity. Forward operation of CII is necessary for maintaining succinate levels low enough to allow the reversible succinyl-CoA ligase reaction to proceed towards ATP (or GTP) synthesis, but on the other hand, CII reversal also occurs reducing fumarate to succinate and oxidizing UQH2 to UQ, the latter favoring CI activity. All other enzymatic reactions in which succinate, fumarate, UQ and UQH2 participate, contribute to CII directionality and ultimately influence CI residual activity.
Limitations of present study
A main concept of the present work is the demonstration that UQ availability dictates CI activity; therefore, manipulation of Q pools by disrupting CoQ biosynthetic pathways could have been argued to lend strong support to the above claim. However, disrupting CoQ biosynthesis leads to impaired mitochondria99; it would be exceedingly difficult to achieve anoxic state in impaired mitochondria due to negligible OXPHOS state of respiration. Thus, we have alternatively relied on limiting vitamin K supplementation to mice; “vitamin K” is actually a group of naphthoquinones that includes menaquinone and phylloquinone100. These two quinones carry electrons in bacteria and plants, respectively, whereas eukaryotes use ubiquinone (CoQ). However, the eukaryotic enzyme ferroptosis suppressor protein 1 (FSP1), a NAD(P)H-ubiquinone reductase reduces both vitamin K quinones and CoQ101 and by doing this, vitamin K may “spare” CoQ pools. Since vitamin K is a regular dietary constituent, we reasoned that by decreasing vitamin K availability in a relatively acute manner (mice were subject to a vitamin K-deficient diet for 1–3 weeks) CoQ pools could be sufficiently diminished but not to the extent of impairing OXPHOS respiration.
Another limitation is that electrochemical, real-time detection of mitochondrial quinone pools cannot be performed in intact, living cells using Q2 (or any other) mediator, due to ‘enclosure’ of mitochondria by the cytosol and plasma membrane. Thus, it is not possible to address in situ CI activity by recording changes in Q levels using the three-electrode system in intact, living cells.
An additional limitation is that mouse liver mitochondrial metabolism differs from other tissues102; to this end, it was shown that CI is dispensable in the adult murine liver. Although this specific aspect does not necessarily diminish the importance or credibility of the present work, it must not be ignored that there could be some other difference downstream from CI just as major as the dispensability of this ETS complex for mouse survival that could confound our interpretations. Relevant to this, our main findings were reproduced in mitochondria isolated from brains and hearts of mice. Finally, the presence of quinone binding sites on CI that are rotenone-insensitive may also confound our interpretations on the effects of this inhibitor on Q changes103–105 reviewed by Lenaz62.
Supplementary Information
Acknowledgements
This work was supported by grants from NKFIH KH129567, NKFIH K135027 and TKP2021-EGA-25 to C.C., grants NKFIH K137563 and TKP2021-EGA-24 to K.K. and from the project NextGen-O2k (Oroboros Instruments) which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement Nº 859770. We would like to acknowledge the support and resources of the Birmingham Metabolic Tracer Analysis Core. T.N.S. has received funding from Childhood Cancer UK, Foundation for Metabolic Cancer Therapies, the Corkin Family Foundation, and Dr. Edward Miller. D. R. was supported by a scholarship from School of PhD Studies of Semmelweis University, project no EFOP-3.6.3-VEKOP-16-2017-00009. We thank Dr. Jakus Zoltan for providing the C57Bl6/J mice.
Author contributions
D.R., D.B., S.N., G.P., N.K., J.R., B.M., B.G., A.K., C.H., T.K., C.D., K.C., A.R., B.C. and C.C. conducted the experiments; J.R., B.M., A.K., M.K. and D.A.T. interpreted the 13C metabolic tracer results; K.K. interpreted the hemostasis results; E.F.V. interpreted the supercomplex assay results; D.A.T., E.G., M.K., N.N. and T.N.S. edited the paper; C.C. designed the experiments and wrote the paper.
Funding
Open access funding provided by Semmelweis University.
Data availability
All data have been deposited at Mendeley (doi: 10.17632/5tj4kymggt.1) and are publicly available as of the date of publication. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact (Christos Chinopoulos; Email: chinopoulos.christos@semmelweis.hu) upon request.
Competing interests
C.C. is a Key Opinion Leader in the project that developed the NextGen-O2k prototype by Oroboros Instruments in the H202 SME phase 2, grant agreement No. 859770. E.G. is the CEO of Oroboros Instruments; T.K. and C.D. were employees at Oroboros Instruments at the time of the experiments. No other authors have competing interest.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-024-51365-4.
References
- 1.Hirst J. Mitochondrial complex I. Annu. Rev. Biochem. 2013;82:551–575. doi: 10.1146/annurev-biochem-070511-103700. [DOI] [PubMed] [Google Scholar]
- 2.Birrell JA, Hirst J. Investigation of NADH binding, hydride transfer, and NAD(+) dissociation during NADH oxidation by mitochondrial complex I using modified nicotinamide nucleotides. Biochemistry. 2013;52:4048–4055. doi: 10.1021/bi3016873. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Blinova K, et al. Mitochondrial NADH fluorescence is enhanced by complex I binding. Biochemistry. 2008;47:9636–9645. doi: 10.1021/bi800307y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Xiao W, Loscalzo J. Metabolic responses to reductive stress. Antioxid. Redox Signal. 2020;32:1330–1347. doi: 10.1089/ars.2019.7803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Zhang J, et al. Accumulation of succinate in cardiac ischemia primarily occurs via canonical Krebs cycle activity. Cell Rep. 2018;23:2617–2628. doi: 10.1016/j.celrep.2018.04.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tyler, D. D. & Gonze, J. Methods in Enzymology. Vol. 10. 75–77 (Academic Press, 1967).
- 7.Sims NR. Rapid isolation of metabolically active mitochondria from rat brain and subregions using Percoll density gradient centrifugation. J. Neurochem. 1990;55:698–707. doi: 10.1111/j.1471-4159.1990.tb04189.x. [DOI] [PubMed] [Google Scholar]
- 8.Chinopoulos C, Starkov AA, Fiskum G. Cyclosporin A-insensitive permeability transition in brain mitochondria: Inhibition by 2-aminoethoxydiphenyl borate. J. Biol. Chem. 2003;278:27382–27389. doi: 10.1074/jbc.M303808200. [DOI] [PubMed] [Google Scholar]
- 9.Smith PK, et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985;150:76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
- 10.Emaus RK, Grunwald R, Lemasters JJ. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: Spectral and metabolic properties. Biochim. Biophys. Acta. 1986;850:436–448. doi: 10.1016/0005-2728(86)90112-x. [DOI] [PubMed] [Google Scholar]
- 11.Krumschnabel G, Eigentler A, Fasching M, Gnaiger E. Use of safranin for the assessment of mitochondrial membrane potential by high-resolution respirometry and fluorometry. Methods Enzymol. 2014;542:163–181. doi: 10.1016/B978-0-12-416618-9.00009-1. [DOI] [PubMed] [Google Scholar]
- 12.Chinopoulos C, et al. Forward operation of adenine nucleotide translocase during F0F1-ATPase reversal: Critical role of matrix substrate-level phosphorylation. FASEB J. 2010;24:2405–2416. doi: 10.1096/fj.09-149898. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Klingenberg, M. Methods of Enzymatic Analysis (ed. Bergmeyer, H.-U.). 531–534 (Academic Press, 1965).
- 14.Rich, P. R. Monitoring Membrane Bounded Systems. (1988).
- 15.Moore AL, Dry IB, Wiskich JT. Measurement of the redox state of the ubiquinone pool in plant mitochondria. FEBS Lett. 1988;235:76–80. doi: 10.1016/0014-5793(88)81237-7. [DOI] [Google Scholar]
- 16.Pallag G, et al. Proline oxidation supports mitochondrial ATP production when complex I is inhibited. Int. J. Mol. Sci. 2022 doi: 10.3390/ijms23095111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Komlódi TCL, Doerrier C, Moore AL, Rich PR, Gnaiger E. Coupling and pathway control of coenzyme Q redox state and respiration in isolated mitochondria. Bioenergy Commun. 2021 doi: 10.26124/bec:2021-0003. [DOI] [Google Scholar]
- 18.Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J. Pharmacol. Pharmacother. 2010;1:87–93. doi: 10.4103/0976-500X.72350. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Clasquin MF, Melamud E, Rabinowitz JD. LC-MS data processing with MAVEN: a metabolomic analysis and visualization engine. Curr. Protoc. Bioinform. 2012;14:14 11. doi: 10.1002/0471250953.bi1411s37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Crane, F. L. & Barr, R. Methods in Enzymology. Vol. 18. 137–165 (Academic Press, 1971).
- 21.Fernandez-Vizarra E, Zeviani M. Blue-native electrophoresis to study the OXPHOS complexes. Methods Mol. Biol. 2021;2192:287–311. doi: 10.1007/978-1-0716-0834-0_20. [DOI] [PubMed] [Google Scholar]
- 22.Jin Q, Bethke CM. Kinetics of electron transfer through the respiratory chain. Biophys. J. 2002;83:1797–1808. doi: 10.1016/S0006-3495(02)73945-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Turunen M, Olsson J, Dallner G. Metabolism and function of coenzyme Q. Biochim. Biophys. Acta. 2004;1660:171–199. doi: 10.1016/j.bbamem.2003.11.012. [DOI] [PubMed] [Google Scholar]
- 24.Galinier A, et al. Biological validation of coenzyme Q redox state by HPLC-EC measurement: Relationship between coenzyme Q redox state and coenzyme Q content in rat tissues. FEBS Lett. 2004;578:53–57. doi: 10.1016/j.febslet.2004.10.067. [DOI] [PubMed] [Google Scholar]
- 25.Yamamoto Y, Yamashita S. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol. Asp. Med. 1997;18(Suppl):S79–84. doi: 10.1016/S0098-2997(97)00007-1. [DOI] [PubMed] [Google Scholar]
- 26.Kroger A, Klingenberg M. The kinetics of the redox reactions of ubiquinone related to the electron-transport activity in the respiratory chain. Eur. J. Biochem. 1973;34:358–368. doi: 10.1111/j.1432-1033.1973.tb02767.x. [DOI] [PubMed] [Google Scholar]
- 27.Kulkarni CA, Brookes PS. Cellular compartmentation and the redox/nonredox functions of NAD. Antioxid. Redox Signal. 2019;31:623–642. doi: 10.1089/ars.2018.7722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Chinopoulos C, et al. A novel kinetic assay of mitochondrial ATP-ADP exchange rate mediated by the ANT. Biophys. J. 2009;96:2490–2504. doi: 10.1016/j.bpj.2008.12.3915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Gutman M, Coles CJ, Singer TP, Casida JE. On the functional organization of the respiratory chain at the dehydrogenase-coenzyme Q junction. Biochemistry. 1971;10:2036–2043. doi: 10.1021/bi00787a011. [DOI] [PubMed] [Google Scholar]
- 30.Gnaiger, E. Mitochondrial Pathways and Respiratory Control: An Introduction to OXPHOS Analysis. 5th ed. (2020).
- 31.Banerjee R, Purhonen J, Kallijarvi J. The mitochondrial coenzyme Q junction and complex III: Biochemistry and pathophysiology. FEBS J. 2022;289:6936–6958. doi: 10.1111/febs.16164. [DOI] [PubMed] [Google Scholar]
- 32.Gnaiger E. Bioenergetics at low oxygen: Dependence of respiration and phosphorylation on oxygen and adenosine diphosphate supply. Respir. Physiol. 2001;128:277–297. doi: 10.1016/s0034-5687(01)00307-3. [DOI] [PubMed] [Google Scholar]
- 33.Drose S, Stepanova A, Galkin A. Ischemic A/D transition of mitochondrial complex I and its role in ROS generation. Biochim. Biophys. Acta. 1857;2016:946–957. doi: 10.1016/j.bbabio.2015.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Kotlyar AB, Vinogradov AD. Slow active/inactive transition of the mitochondrial NADH-ubiquinone reductase. Biochim. Biophys. Acta. 1990;1019:151–158. doi: 10.1016/0005-2728(90)90137-s. [DOI] [PubMed] [Google Scholar]
- 35.Kiss G, et al. Mitochondrial diaphorases as NAD(+) donors to segments of the citric acid cycle that support substrate-level phosphorylation yielding ATP during respiratory inhibition. FASEB J. 2014;28:1682–1697. doi: 10.1096/fj.13-243030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Chinopoulos C. Mitochondrial consumption of cytosolic ATP: Not so fast. FEBS Lett. 2011;585:1255–1259. doi: 10.1016/j.febslet.2011.04.004. [DOI] [PubMed] [Google Scholar]
- 37.Chinopoulos C. The, "B space" of mitochondrial phosphorylation. J. Neurosci. Res. 2011;89:1897–1904. doi: 10.1002/jnr.22659. [DOI] [PubMed] [Google Scholar]
- 38.Ino T, Nishioka T, Miyoshi H. Characterization of inhibitor binding sites of mitochondrial complex I using fluorescent inhibitor. Biochim. Biophys. Acta. 2003;1605:15–20. doi: 10.1016/s0005-2728(03)00060-4. [DOI] [PubMed] [Google Scholar]
- 39.Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: An overview. Biochim. Biophys. Acta. 1998;1364:222–235. doi: 10.1016/s0005-2728(98)00029-2. [DOI] [PubMed] [Google Scholar]
- 40.Kiss G, et al. The negative impact of alpha-ketoglutarate dehydrogenase complex deficiency on matrix substrate-level phosphorylation. FASEB J. 2013;27:2392–2406. doi: 10.1096/fj.12-220202. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Spinelli JB, et al. Fumarate is a terminal electron acceptor in the mammalian electron transport chain. Science. 2021;374:1227–1237. doi: 10.1126/science.abi7495. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Ansari F, et al. Quantification of NADH:ubiquinone oxidoreductase (complex I) content in biological samples. J. Biol. Chem. 2021;297:101204. doi: 10.1016/j.jbc.2021.101204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Capaldi RA. Arrangement of proteins in the mitochondrial inner membrane. Biochim. Biophys. Acta. 1982;694:291–306. doi: 10.1016/0304-4157(82)90009-0. [DOI] [PubMed] [Google Scholar]
- 44.Fato R, et al. Steady-state kinetics of the reduction of coenzyme Q analogs by complex I (NADH:ubiquinone oxidoreductase) in bovine heart mitochondria and submitochondrial particles. Biochemistry. 1996;35:2705–2716. doi: 10.1021/bi9516034. [DOI] [PubMed] [Google Scholar]
- 45.Lass A, Sohal RS. Comparisons of coenzyme Q bound to mitochondrial membrane proteins among different mammalian species. Free Radic. Biol. Med. 1999;27:220–226. doi: 10.1016/s0891-5849(99)00085-4. [DOI] [PubMed] [Google Scholar]
- 46.Trumpower BL. New concepts on the role of ubiquinone in the mitochondrial respiratory chain. J. Bioenergy Biomembr. 1981;13:1–24. doi: 10.1007/BF00744743. [DOI] [PubMed] [Google Scholar]
- 47.Lee GY, He DY, Yu L, Yu CA. Identification of the ubiquinone-binding domain in QPs1 of succinate-ubiquinone reductase. J. Biol. Chem. 1995;270:6193–6198. doi: 10.1074/jbc.270.11.6193. [DOI] [PubMed] [Google Scholar]
- 48.Vinogradov AD, et al. Energy-dependent Complex I-associated ubisemiquinones in submitochondrial particles. FEBS Lett. 1995;370:83–87. doi: 10.1016/0014-5793(95)00803-h. [DOI] [PubMed] [Google Scholar]
- 49.Vinogradov AD. Catalytic properties of the mitochondrial NADH-ubiquinone oxidoreductase (complex I) and the pseudo-reversible active/inactive enzyme transition. Biochim. Biophys. Acta. 1998;1364:169–185. doi: 10.1016/s0005-2728(98)00026-7. [DOI] [PubMed] [Google Scholar]
- 50.Kolesova GM, Sokol'nikov AA, Kodentsova VM, Klimova OA, Sergeev IN. The effect of vitamin K deficiency in rats on various enzyme systems participating in energy metabolism. Vopr. Med. Khim. 1988;34:46–51. [PubMed] [Google Scholar]
- 51.Thijssen HH, Drittij-Reijnders MJ. Vitamin K distribution in rat tissues: Dietary phylloquinone is a source of tissue menaquinone-4. Br. J. Nutr. 1994;72:415–425. doi: 10.1079/bjn19940043. [DOI] [PubMed] [Google Scholar]
- 52.Marder, V. J. A., William C., Bennett, J.S., Schulman, S. & White II, G.C. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 1424–1433 (Lippincott Williams & Wilkins (LWW), 2012).
- 53.Balendran CA, et al. Prothrombin time is predictive of low plasma prothrombin concentration and clinical outcome in patients with trauma hemorrhage: Analyses of prospective observational cohort studies. Scand. J. Trauma Resusc. Emerg. Med. 2017;25:30. doi: 10.1186/s13049-016-0332-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Card DJ, Gorska R, Harrington DJ. Laboratory assessment of vitamin K status. J. Clin. Pathol. 2020;73:70–75. doi: 10.1136/jclinpath-2019-205997. [DOI] [PubMed] [Google Scholar]
- 55.Ronchi JA, et al. A spontaneous mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial redox abnormalities. Free Radic. Biol. Med. 2013;63:446–456. doi: 10.1016/j.freeradbiomed.2013.05.049. [DOI] [PubMed] [Google Scholar]
- 56.Sanadi DR, Fluharty AL. On the mechanism of oxidative phosphorylation. VII. The energy-requiring reduction of pyridine nucleotide by succinate and the energy-yielding oxidation of reduced pyridine nucleotide by fumarate. Biochemistry. 1963;2:523–528. doi: 10.1021/bi00903a023. [DOI] [PubMed] [Google Scholar]
- 57.Chinopoulos C. Succinate in ischemia: Where does it come from? Int. J. Biochem. Cell Biol. 2019;115:105580. doi: 10.1016/j.biocel.2019.105580. [DOI] [PubMed] [Google Scholar]
- 58.Papa S, Tager JM, Francavilla A, De Haan EJ, Quagliariello E. Control of glutamate dehydrogenase activity during glutamate oxidation in isolated rat-liver mitochondria. Biochim. Biophys. Acta (BBA)-Bioenerg. 1967;131:14–28. doi: 10.1016/0005-2728(67)90027-8. [DOI] [Google Scholar]
- 59.Johnson RN, Chappell JB. The transport of inorganic phosphate by the mitochondrial dicarboxylate carrier. Biochem. J. 1973;134:769–774. doi: 10.1042/bj1340769. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Briere JJ, Schlemmer D, Chretien D, Rustin P. Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem. Biophys. Res. Commun. 2004;316:1138–1142. doi: 10.1016/j.bbrc.2004.03.002. [DOI] [PubMed] [Google Scholar]
- 61.Chen M, Liu BL, Gu LQ, Zhu QS. The effect of ring substituents on the mechanism of interaction of exogenous quinones with the mitochondrial respiratory chain. Biochim. Biophys. Acta. 1986;851:469–474. doi: 10.1016/0005-2728(86)90083-6. [DOI] [PubMed] [Google Scholar]
- 62.Lenaz G. Quinone specificity of complex I. Biochim. Biophys. Acta. 1998;1364:207–221. doi: 10.1016/s0005-2728(98)00028-0. [DOI] [PubMed] [Google Scholar]
- 63.Palmieri F, Prezioso G, Quagliariello E, Klingenberg M. Kinetic study of the dicarboxylate carrier in rat liver mitochondria. Eur. J. Biochem. 1971;22:66–74. doi: 10.1111/j.1432-1033.1971.tb01515.x. [DOI] [PubMed] [Google Scholar]
- 64.Quagliariello E, Palmieri F. Control of succinate oxidation by succinate-uptake by rat-liver mitochondria. Eur. J. Biochem. 1968;4:20–27. doi: 10.1111/j.1432-1033.1968.tb00167.x. [DOI] [PubMed] [Google Scholar]
- 65.Diaz F, Enriquez JA, Moraes CT. Cells lacking Rieske iron-sulfur protein have a reactive oxygen species-associated decrease in respiratory complexes I and IV. Mol. Cell Biol. 2012;32:415–429. doi: 10.1128/MCB.06051-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Guaras A, et al. The CoQH2/CoQ ratio serves as a sensor of respiratory chain efficiency. Cell Rep. 2016;15:197–209. doi: 10.1016/j.celrep.2016.03.009. [DOI] [PubMed] [Google Scholar]
- 67.Lapuente-Brun E, et al. Supercomplex assembly determines electron flux in the mitochondrial electron transport chain. Science. 2013;340:1567–1570. doi: 10.1126/science.1230381. [DOI] [PubMed] [Google Scholar]
- 68.Fernandez-Vizarra E, et al. Two independent respiratory chains adapt OXPHOS performance to glycolytic switch. Cell Metab. 2022;34:1792–1808e1796. doi: 10.1016/j.cmet.2022.09.005. [DOI] [PubMed] [Google Scholar]
- 69.Gnaiger, E. Surviving Hypoxia: Mechanisms of Control and Adaptation (eds. Lutz, P.L., Hochachka, P.W., Sick, T., Rosenthal, M., Van den Thillart, G.). 77–109 (CRC Press, 1993).
- 70.Kohlhauer M, et al. Metabolomic profiling in acute ST-segment-elevation myocardial infarction identifies succinate as an early marker of human ischemia-reperfusion injury. J. Am. Heart Assoc. 2018 doi: 10.1161/JAHA.117.007546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Seyfried TN, Arismendi-Morillo G, Mukherjee P, Chinopoulos C. On the origin of ATP synthesis in cancer. iScience. 2020;23:101761. doi: 10.1016/j.isci.2020.101761. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Chinopoulos C. Acute sources of mitochondrial NAD(+) during respiratory chain dysfunction. Exp. Neurol. 2020;327:113218. doi: 10.1016/j.expneurol.2020.113218. [DOI] [PubMed] [Google Scholar]
- 73.Gnaiger E, Mendez G, Hand SC. High phosphorylation efficiency and depression of uncoupled respiration in mitochondria under hypoxia. Proc. Natl. Acad. Sci. USA. 2000;97:11080–11085. doi: 10.1073/pnas.97.20.11080. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Altea-Manzano P, et al. Reversal of mitochondrial malate dehydrogenase 2 enables anaplerosis via redox rescue in respiration-deficient cells. Mol. Cell. 2022;82:4537–4547.e4537. doi: 10.1016/j.molcel.2022.10.005. [DOI] [PubMed] [Google Scholar]
- 75.Westbrook RL, et al. Proline synthesis through PYCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions. Cell Rep. 2022;38:110320. doi: 10.1016/j.celrep.2022.110320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Hoberman HD, Prosky L. Evidence of reduction of fumarate to succinate in perfused rat liver under conditions of reduced O2 tension. Biochim. Biophys. Acta. 1967;148:392–399. doi: 10.1016/0304-4165(67)90135-3. [DOI] [PubMed] [Google Scholar]
- 77.Hohl C, Oestreich R, Rosen P, Wiesner R, Grieshaber M. Evidence for succinate production by reduction of fumarate during hypoxia in isolated adult rat heart cells. Arch. Biochem. Biophys. 1987;259:527–535. doi: 10.1016/0003-9861(87)90519-4. [DOI] [PubMed] [Google Scholar]
- 78.Chouchani ET, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431–435. doi: 10.1038/nature13909. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Hochachka PW, Dressendorfer RH. Succinate accumulation in man during exercise. Eur. J. Appl. Physiol. Occup. Physiol. 1976;35:235–242. doi: 10.1007/BF00423282. [DOI] [PubMed] [Google Scholar]
- 80.Hochachka PW, Owen TG, Allen JF, Whittow GC. Multiple end products of anaerobiosis in diving vertebrates. Comp. Biochem. Physiol. B. 1975;50:17–22. doi: 10.1016/0305-0491(75)90292-8. [DOI] [PubMed] [Google Scholar]
- 81.Tretter L, Patocs A, Chinopoulos C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. Biochim. Biophys. Acta. 1857;2016:1086–1101. doi: 10.1016/j.bbabio.2016.03.012. [DOI] [PubMed] [Google Scholar]
- 82.Ravasz D, et al. Reduction of 2-methoxy-1,4-naphtoquinone by mitochondrially-localized Nqo1 yielding NAD(+) supports substrate-level phosphorylation during respiratory inhibition. Biochim. Biophys. Acta Bioenerg. 1859;2018:909–924. doi: 10.1016/j.bbabio.2018.05.002. [DOI] [PubMed] [Google Scholar]
- 83.Pell VR, Chouchani ET, Murphy MP, Brookes PS, Krieg T. Moving forwards by blocking back-flow: The Yin and Yang of MI therapy. Circ. Res. 2016;118:898–906. doi: 10.1161/CIRCRESAHA.115.306569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Idstrom JP, Soussi B, Elander A, Bylund-Fellenius AC. Purine metabolism after in vivo ischemia and reperfusion in rat skeletal muscle. Am. J. Physiol. 1990;258:H1668–1673. doi: 10.1152/ajpheart.1990.258.6.H1668. [DOI] [PubMed] [Google Scholar]
- 85.Gerencser AA, et al. Quantitative measurement of mitochondrial membrane potential in cultured cells: Calcium-induced de- and hyperpolarization of neuronal mitochondria. J. Physiol. 2012;590:2845–2871. doi: 10.1113/jphysiol.2012.228387. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Martinez-Reyes I, et al. Mitochondrial ubiquinol oxidation is necessary for tumour growth. Nature. 2020;585:288–292. doi: 10.1038/s41586-020-2475-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Vaupel P, Harrison L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(Suppl 5):4–9. doi: 10.1634/theoncologist.9-90005-4. [DOI] [PubMed] [Google Scholar]
- 88.Wise DR, Thompson CB. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem. Sci. 2010;35:427–433. doi: 10.1016/j.tibs.2010.05.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Titov DV, et al. Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio. Science. 2016;352:231–235. doi: 10.1126/science.aad4017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Urra FA, Munoz F, Lovy A, Cardenas C. The mitochondrial complex(I)ty of cancer. Front. Oncol. 2017;7:118. doi: 10.3389/fonc.2017.00118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.Greene J, Segaran A, Lord S. Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications. Semin. Cancer Biol. 2022;86:851–859. doi: 10.1016/j.semcancer.2022.02.002. [DOI] [PubMed] [Google Scholar]
- 92.Babot M, Birch A, Labarbuta P, Galkin A. Characterisation of the active/de-active transition of mitochondrial complex I. Biochim. Biophys. Acta. 1837;2014:1083–1092. doi: 10.1016/j.bbabio.2014.02.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Babot M, Galkin A. Molecular mechanism and physiological role of active-deactive transition of mitochondrial complex I. Biochem. Soc. Trans. 2013;41:1325–1330. doi: 10.1042/BST20130088. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Stepanova A, et al. Deactivation of mitochondrial complex I after hypoxia-ischemia in the immature brain. J. Cereb. Blood Flow Metab. 2019;39:1790–1802. doi: 10.1177/0271678X18770331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Galkin A, Abramov AY, Frakich N, Duchen MR, Moncada S. Lack of oxygen deactivates mitochondrial complex I: Implications for ischemic injury? J. Biol. Chem. 2009;284:36055–36061. doi: 10.1074/jbc.M109.054346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 96.Lambeth DO, Tews KN, Adkins S, Frohlich D, Milavetz BI. Expression of two succinyl-CoA synthetases with different nucleotide specificities in mammalian tissues. J. Biol. Chem. 2004;279:36621–36624. doi: 10.1074/jbc.M406884200. [DOI] [PubMed] [Google Scholar]
- 97.Kacso G, et al. Two transgenic mouse models for beta-subunit components of succinate-CoA ligase yielding pleiotropic metabolic alterations. Biochem. J. 2016;473:3463–3485. doi: 10.1042/BCJ20160594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.St-Pierre J, Brand MD, Boutilier RG. Mitochondria as ATP consumers: Cellular treason in anoxia. Proc. Natl. Acad. Sci. USA. 2000;97:8670–8674. doi: 10.1073/pnas.140093597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Hargreaves I, Heaton RA, Mantle D. Disorders of human coenzyme Q10 metabolism: An overview. Int. J. Mol. Sci. 2020 doi: 10.3390/ijms21186695. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Shearer MJ, Okano T. Key pathways and regulators of vitamin K function and intermediary metabolism. Annu. Rev. Nutr. 2018;38:127–151. doi: 10.1146/annurev-nutr-082117-051741. [DOI] [PubMed] [Google Scholar]
- 101.Mishima E, et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature. 2022 doi: 10.1038/s41586-022-05022-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Lesner NP, et al. Differential requirements for mitochondrial electron transport chain components in the adult murine liver. eLife. 2022 doi: 10.7554/eLife.80919. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Degli Esposti M, et al. The specificity of mitochondrial complex I for ubiquinones. Biochem. J. 1996;313(Pt 1):327–334. doi: 10.1042/bj3130327. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Kotlyar AB, Gutman M. The effect of delta mu H+ on the interaction of rotenone with complex I of submitochondrial particles. Biochim. Biophys. Acta. 1992;1140:169–174. doi: 10.1016/0005-2728(92)90006-n. [DOI] [PubMed] [Google Scholar]
- 105.King MS, Sharpley MS, Hirst J. Reduction of hydrophilic ubiquinones by the flavin in mitochondrial NADH:ubiquinone oxidoreductase (Complex I) and production of reactive oxygen species. Biochemistry. 2009;48:2053–2062. doi: 10.1021/bi802282h. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Vajda S, et al. A re-evaluation of the role of matrix acidification in uncoupler-induced Ca2+ release from mitochondria. FEBS J. 2009;276:2713–2724. doi: 10.1111/j.1742-4658.2009.06995.x. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data have been deposited at Mendeley (doi: 10.17632/5tj4kymggt.1) and are publicly available as of the date of publication. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact (Christos Chinopoulos; Email: chinopoulos.christos@semmelweis.hu) upon request.